Abstracts Archive - Page 559 of 2425 - ACR Meeting Abstracts

Abstract Number: 0098 • ACR Convergence 2021
Patients with Chronic Inflammatory Rheumatic Diseases Report a Lower Frequency of Infections Than Controls and They Protect Themselves Well Against SARS-CoV-2 Transmission
Iulia Roman, Ioana Andreica, Xenofon Baraliakos, Uta Kiltz and Juergen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The SARS-CoV-2 pandemic has affected life in most countries around the world for more than a year now. It is not entirely clear if…
Abstract Number: 0101 • ACR Convergence 2021
Herpes Zoster Recombinant Zoster Vaccination Among Adults Age ≥50 Years with Immune Mediated Inflammatory Diseases in the United States
Jessica Leung¹, Tara Anderson¹, Kathleen Dooling¹, Fenglong Xie² and Jeffrey Curtis³, ¹Centers for Disease Control, Atlanta, GA, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Persons with immune mediated Inflammatory diseases (IMIDs) are at increased risk of developing herpes zoster (HZ) and postherpetic neuralgia. In 2018, CDC recommended a…
Abstract Number: 0104 • ACR Convergence 2021
Adverse Events of First SARS-CoV-2 Vaccinations Are Comparable for Patients with Autoimmune Diseases and the General Population
Laura Boekel¹, Laura Kummer², Koos van Dam², Femke Hooijberg¹, Zoé van Kempen², Erik Vogelzang², Luuk Wieske², Filip Eftimov², Ronald van Vollenhoven³, Taco Kuijpers², Marieke van Ham⁴, Sander Tas⁵, Joep Killestein², Maarten Boers⁶, Mike Nurmohamed⁷, Theo Rispens⁴ and Gertjan Wolbink¹, ¹Reade, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Sanquin, Amsterdam, Netherlands, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands, ⁶Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁷Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands
Background/Purpose: Clinical trials on efficacy and safety of SARS-CoV-2 vaccines did not include patients with autoimmune diseases. We previously demonstrated that concerns of adverse events…
Abstract Number: 0103 • ACR Convergence 2021
Patients with Inflammatory Rheumatic Diseases Are at Increased Risk of COVID-19 Related Hospitalization: Data from a Prospective Controlled Cohort Study
Laura Boekel¹, Femke Hooijberg¹, Erik Vogelzang², Maureen Leeuw¹, Sadaf Atiqi¹, Ronald van Vollenhoven³, Alexandre Voskuyl², Irene van der Horst-Bruinsma², Willem Lems¹, Taco Kuijpers², Marieke van Ham⁴, Luuk Wieske², Filip Eftimov², Maurice Steenhuis⁴, Sofie Keijzer⁴, Olvi Christianawati⁴, Floris Loeff⁴, Sander Tas⁵, Mike Nurmohamed⁶, Theo Rispens⁴ and Gertjan Wolbink¹, ¹Reade, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Sanquin, Amsterdam, Netherlands, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands, ⁶Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands
Background/Purpose: Retrospective studies have suggested that patients with rheumatic diseases may be at increased risk of severe COVID-19 related disease, and that this risk may…
Abstract Number: 0102 • ACR Convergence 2021
Differential Impact of TNFi, JAKi and Rituximab on the Outcome of SARS-CoV-2 Infection in RMD Patients
Anne Regierer¹, Rebecca Hasseli², Martin Schaefer¹, Bimba Franziska Hoyer³, Andreas Krause⁴, Hanns-Martin Lorenz⁵, Alexander Pfeil⁶, Jutta Richter⁷, Tim Schmeiser⁸, Anja Strangfeld⁹, Hendrik Schulze-Koops¹⁰, Reinhard Voll¹¹, Christof Specker¹² and Ulf Müller-Ladner¹³, ¹German Rheumatism Research Center, Berlin, Germany, ²Justus-Liebig-University Giessen, Bad Nauheim, Germany, ³Universittsklinikum Schleswig-Holstein, Kiel, Germany, ⁴Immanuel Hospital, Berlin, Germany, ⁵University Hospital Heidelberg Germany, Heidelberg, Germany, ⁶Friedrich Schiller University Jena, Jena, Germany, ⁷Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ⁸Private Practice, Cologne, Germany, ⁹Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ¹⁰Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹¹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹²Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ¹³JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany
Background/Purpose: Due to the impressive efforts of the global scientific rheumatology community, increasing evidence about inflammatory rheumatic and musculoskeletal diseases (RMD) specific risk factors in…
Abstract Number: 0097 • ACR Convergence 2021
Outcome of SARS-CoV-2 Infection in Patients with Rheumatoid Arthritis Under Treatment with Janus Kinase Inhibitors Compared to Tumour Necrosis Factor Inhibitors
Rebecca Hasseli¹, Bimba Franziska Hoyer², Hanns-Martin Lorenz³, Alexander Pfeil⁴, Anne Regierer⁵, Jutta Richter⁶, Tim Schmeiser⁷, Anja Strangfeld⁸, Reinhard Voll⁹, Andreas Krause¹⁰, Hendrik Schulze-Koops¹¹, Christof Specker¹² and Ulf Müller-Ladner¹³, ¹Justus-Liebig-University Giessen, Bad Nauheim, Germany, ²Universittsklinikum Schleswig-Holstein, Kiel, Germany, ³University Hospital Heidelberg Germany, Heidelberg, Germany, ⁴Friedrich Schiller University Jena, Jena, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ⁷Private Practice, Cologne, Germany, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹⁰Immanuel Hospital, Berlin, Germany, ¹¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹²Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ¹³JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany
Background/Purpose: Janus kinase inhibitors (JAK-i) offer a potent mode of action to treat rheumatic diseases. Little is known on the course and outcome of SARS-CoV-2…
Abstract Number: 0108 • ACR Convergence 2021
Efficacy of SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis
Akhil Sood¹, Vijaya Murthy¹ and Emilio Gonzalez², ¹University of Texas Medical Branch, League City, TX, ²University of Texas Medical Branch (utmb Health), Galveston, TX
Background/Purpose: The mRNA-based SARS-CoV-2 vaccine has shown efficacy in large vaccine trials. However, patients on immunosuppressive therapies including those with rheumatic disease (RD) were excluded.…
Abstract Number: 0107 • ACR Convergence 2021
Acceptability of the COVID-19 Vaccine in Patients with Rheumatic Diseases and Healthcare Professionals in 19 Arab Countries
Lina El Kibbi¹, Mona Metawee¹, Ihsane Hmamouchi², Nizar Abdulateef³, Hussein Halabi⁴, Mervat Eissa⁵, Manal El Rakawi⁶, Basel Masri⁷, Fatemah Abutiban⁸, Wafa Hamdi⁹, Asal Adnan³, Antonella Abi Najm¹⁰, Renaud Felten¹¹, Laurent Arnaud¹¹ and Nelly Ziade¹², ¹Specialized Medical Center, Riyadh, Saudi Arabia, ²Rheumatology Unit, Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, ³Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq, ⁴King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, ⁵Cairo University, Cairo, Egypt, Cairo, Egypt, ⁶Rheumatology Department, Douera Hospital, Faculty of Medicine, Saad Dahlab, Blida, Algeria, ⁷Jordan Hospital, Amman, Jordan, ⁸Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah Hospital, Kuwait City, Kuwait, ⁹Rheumatology Department, Kassab Institute of Orthopedics, UR17SP04, Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia, ¹⁰Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon, ¹¹Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, ¹²Rheumatology Department, Saint-Joseph Medical University and Hotel-Dieu de France Hospital, Beirut, Lebanon
Background/Purpose: The first COVID-19 vaccines were authorized in December 2020. However, their acceptability remains debated and has never been evaluated in patients with chronic rheumatic…
Abstract Number: 0105 • ACR Convergence 2021
Most Patients with Spondylitis Accept COVID-19 Vaccination and Few Experience Disease Exacerbation After Immunization
Rachel Higgins¹, Hedley Hamilton², Michael Weisman³, John Reveille⁴, Kimbery Ogle¹, Cassie Shafer⁵, Elin Aslanyan⁵, Richard Howard⁵, Dongseok Choi¹, James T. Rosenbaum⁶ and Kevin Winthrop¹, ¹Oregon Health & Science University, Portland, OR, ²Any-3 Ltd, London, United Kingdom, ³Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁵Spondylitis Association of America, Encino, CA, ⁶Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMDs) remain at an increased risk of morbidity and mortality from vaccine preventable infections, often as a result…
Abstract Number: 0109 • ACR Convergence 2021
COVID-19 Infection and Outcomes in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis
Akhil Sood¹, Ronak Gandhi², Vijaya Murthy¹, Emilio Gonzalez³ and Mukaila Raji², ¹University of Texas Medical Branch, League City, TX, ²University of Texas Medical Branch, Galveston, TX, ³University of Texas Medical Branch (utmb Health), Galveston, TX
Background/Purpose: Early studies published at the beginning of COVID-19 pandemic suggested lower risk of COVID-19 and less severe disease course in patients with rheumatic diseases…
Abstract Number: 0111 • ACR Convergence 2021
Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study
Ana Michelle Avina-Galindo¹, Shelby Marozoff¹, Zahra Fazal¹, Jessie Kwan¹, Na Lu¹, Alison Hoens², Diane Lacaille³, Jacek Kopec⁴, Hui Xie⁵ and J. Antonio Avina-Zubieta³, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada Arthritis Patient Advisory Board, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: New cases of the novel coronavirus disease (COVID-19) continue to occur even one year since the declaration of a global pandemic. Although most people…
Abstract Number: 0110 • ACR Convergence 2021
Mortality in 2020 Due to COVID-19 in U.S. Adults with Rheumatic Diseases: Data from a Large, National, Multi-Rheumatic Disease Registry
Kaleb Michaud¹, Sofia Pedro², Rebecca Schumacher³, Mukund Kumar¹, Bryant England¹ and Alison Freifeld¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Forward Databank, Wichita
Background/Purpose: Recent studies have detailed the excess death due to COVID-19 during the pandemic, yet few have examined these rates within a rheumatic disease population…
Abstract Number: 0106 • ACR Convergence 2021
COVID-19 Mortality and Hospitalization Risk in Patients with Rheumatic Diseases: A Single Center Retrospective Cohort Study
Mousa Albalwi, Ben Brintz, Srinivasan Beddhu, Guo Wei and Julie Thomas, University of Utah, Salt Lake City, UT
Background/Purpose: Following SARS-CoV-2 infection, patients with rheumatic diseases seem to have similar or slightly poorer outcomes compared with those without rheumatic disease. However, robust data…
Abstract Number: 0100 • ACR Convergence 2021
Safety of COVID-19 Vaccines After First Vaccination in Patients with Rheumatic Diseases in a Patient Reported Survey
Rebecca Hasseli¹, Bimba Franziska Hoyer², Hanns-Martin Lorenz³, Alexander Pfeil⁴, Jutta Richter⁵, Anne Regierer⁶, Tim Schmeiser⁷, Anja Strangfeld⁸, Reinhard Voll⁹, Andreas Krause¹⁰, Hendrik Schulze-Koops¹¹, Ulf Müller-Ladner¹² and Christof Specker¹³, ¹Justus-Liebig-University Giessen, Bad Nauheim, Germany, ²Universittsklinikum Schleswig-Holstein, Kiel, Germany, ³University Hospital Heidelberg Germany, Heidelberg, Germany, ⁴Friedrich Schiller University Jena, Jena, Germany, ⁵Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ⁶German Rheumatism Research Center, Berlin, Germany, ⁷Private Practice, Cologne, Germany, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹⁰Immanuel Hospital, Berlin, Germany, ¹¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹²JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ¹³Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany
Background/Purpose: Among patients with rheumatic and musculoskeletal diseases (RMDs) and their treating physicians, concerns prevail about the effectiveness and safety of vaccination against COVID-19, especially…
Abstract Number: 0081 • ACR Convergence 2021
Thrombin Generation Assay and Lupus Anticoagulant Identify Different Populations of Patients with Antiphospholipid Antibodies
Massimo Radin¹, Alice Barinotti¹, Irene Cecchi², Silvia Grazietta Foddai¹, Elena Rubini¹, Dario Roccatello¹, Elisa Menegatti¹ and Savino Sciascia¹, ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: Risk stratification in patients with antiphospholipid antibodies (aPL) remains a clinical challenge. We aim to evaluate the role of Thrombin Generation Assay (TGA) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].